Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.30 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN4A | P35499 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169056 | 0.90 | SCN3A (0.34) | SCN9ASCN3ASCN5ASCN4A | |
| SCHEMBL6173375 | 0.88 | TDP1 (0.37) | — | |
| SCHEMBL6169151 | 0.82 | RXFP2 (0.39) | — | |
| SCHEMBL6170090 | 0.80 | F10 (0.41) | — | |
| SCHEMBL6168830 | 0.80 | F10 (0.36) | GPR119KIF18A | |
| SCHEMBL7667295 | 0.79 | HTR1A (0.32) | GPR119ATMKIF18AHTR1AHTR7 | |
| SCHEMBL6171161 | 0.76 | NR1H4 (0.45) | — | |
| SCHEMBL6168757 | 0.75 | F10 (0.43) | — | |
| SCHEMBL6170084 | 0.73 | GPR119 (0.36) | GPR119KIF18A | |
| SCHEMBL7089068 | 0.73 | GPR119 (0.36) | GPR119KIF18A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019045-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20030078431-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2003-04-24 | — | — | US | disclosed |
| US-6500851-B2 | ANTICOAGULANT IN MAMMLS | ELI LILLY AND COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020173518-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-11-21 | — | — | US | disclosed |
| US-6372759-B1 | BLOOD COAGULATION FACTOR XA FOR MAMMALS | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| WO-1999000128-A9 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173518-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | GPR119 1388/4885MET 4311/4885ATM 2952/4885 |
| US-20030078431-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | GPR119 1388/4885MET 4311/4885ATM 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.